Secondary prevention of heart disease with statins

BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7501.1208-c (Published 19 May 2005) Cite this as: BMJ 2005;330:1208

Authors' reply

  1. Shah Ebrahim (Shah.Ebrahim@bristol.ac.uk), professor,
  2. Li Wei, research fellow,
  3. Peter D Davey, professor,
  4. Thomas M MacDonald, professor,
  5. Frank M Sullivan, professor
  1. Department of Social Medicine, University of Bristol, Bristol BS8 2PR
  2. Ninewells Hospital and Medical School, Dundee DD1 9SY
  3. Tayside Centre for General Practice, University of Dundee, Dundee DD2 4BF

    EDITOR—There is no substitute for properly randomised controlled trials in evaluating the effects of drug treatments. But trial selection criteria may make patients studied substantially different from those who will receive treatment in clinical practice. For example, in the Medical Research Council's mild hypertension trial cardiovascular mortality rates were similar to those of normotensive men in the general population.1 Examining the associations between treatment and outcome in typical patients is potentially useful in understanding generalisability …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription